01:23 PM EDT, 05/05/2025 (MT Newswires) -- Voyager Acquisition's ( VACH ) planned merger target Veraxa Biotech on Monday said it entered a co-discovery alliance with OmniAb ( OABI ) to develop a bispecific antibody drug conjugate targeting solid tumors.

Veraxa will lead the program, using OmniAb's ( OABI ) transgenic antibody discovery platform to identify antibody leads for two cancer targets, the company said.

The resulting drug candidate will be jointly owned, and both parties will share any future revenues from development, licensing, or commercialization.

Price: 10.30, Change: +0.02, Percent Change: +0.17